Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

President Donald Trump’s penchant for tariffs as a negotiating tool was on full display when he slapped a 25% tariff on ...

Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.

Researchers from Universidade Estadual da Paraíba, Universidade Federal da Paraiba and affiliated organizations presented the ...

Scientists at the University of Pittsburgh have tested a broadly neutralizing antibody (bnAb) that binds the stem of a protein against H5N1 avian influenza, which prevented severe disease in nonhuman ...

The EU’s Medical Device Coordination Group issued a guidance on the types of products that qualify as in vitro diagnostics (IVDs), including some important distinctions even in instances in which a ...

Concluding a two-year journey, Baxter International Inc.’s kidney care unit finally separated from the company and started a new life as Vantive, following the closing on Jan. 31 of its $3.8 billion ...

Biopharma deal value continued its upward trend in 2024, reaching $230.53 billion, a 6% increase from $217.69 billion in 2023, setting a new record in BioWorld’s data. Deal volume also grew, with ...

Researchers from Ocean University of China and Qingdao Marine Science and Technology Center published data from a preclinical study that investigated the impact of the quinazolinone derivative MR-2938 ...

Chinese researchers and their collaborators have published data on the bifunctional antibody JS-201, which exerts dual targeting of PD-1 and TGF-β signaling, for the potential treatment of cancer and ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...